[1] 安澜,曾红梅,郑荣寿,等. 2015年中国肝癌流行情况分析[J]. 中华肿瘤杂志,2019,41(10): 721-727.
[2] Sung H, Ferlay J, Siegel RL,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin,2021,71(3):209-249.
[3] 夏永祥,张峰,李相成, 等. 原发性肝癌10966例外科治疗分析. 中华外科杂志, 2021,59(1): 6-17.
[4] Zhong JH, Peng NF, You XM, et al. Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study[J]. Oncotarget, 2017, 8(11): 18296-18302.
[5] Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma[J]. J Hepatol,2023,79(2): 506-515.
[6] 孙惠川,谢青,荚卫东,等. 肝癌转化治疗中国专家共识(2021版)[J]. 中国实用外科杂志,2021,41(6): 618-632.
[7] 中国医疗保健国际交流促进会肝脏肿瘤分会,中国医学科学院北京协和医学院肿瘤医院消化道肿瘤多学科协作组. 肝细胞癌新辅助及转化治疗中国专家共识[J].肝癌电子杂志,2022,9(1):23-28.
[8] 中华预防医学会肝胆胰疾病预防与控制专业委员会,中国抗癌协会肝癌专业委员会,北京医学会外科学分会肝脏学组等. 基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识(2021版)[J].中华肝胆外科杂志,2021,27(4):241-251.
[9] 国家卫生健康委办公厅.原发性肝癌诊疗指南(2022年版)[J].中华外科杂志,2022,60(04):273-309.
[10] Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma[J]. N Engl J Med 2020; 382(20): 1894-1905.
[11] Qadan M, Kothary N, Sangro B, et al. The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis[J]. Am Soc Clin Oncol Educ Book,2020,40: 1-8.
[12] Sun HC, Zhu XD, Huang cheng,et al. Early tumor marker decrease to predict the efficacy of combination therapy with lenvatinib plus anti-PD-1 antibodies in unresectable hepatocellular carcinoma (uHCC)[J]. J Clin Oncol,2021,39(3_suppl): 304.
[13] Wen T, Jin C, Facciorusso A, et al. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus[J]. Hepatobiliary Surg Nutr,2018,7(5): 353-371.
[14] 肖永胜,郭磊,周俭.原发性肝癌新辅助治疗进展[J].腹部外科,2021,34(01):1-3+9.
[15] Kudo M, et al. Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation[J]. J Clin Oncol,2023,41(16_suppl): 4002.
[16] Chen JH, et al. Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse (LANCE): Updated results from a multi-center prospective cohort study[J]. J Clin Oncol,2020, 38(15_suppl): 4580. |
